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Transactivation  of the Interleukin-la Gene Promoter by Human T-cell Leukemia Virus Type I Tax in T Cells 
To the Editor: 
Tax is a  40-kD  nuclear  phosphoprotein,  encoded  by the pX region 
of the  human  T-cell  leukemia  virus  type  I  (HTLV-I)  genome,  that 
induces  viral  transcription  and  also  transactivates  a  variety  of cellular 
genes,  including  those for  interleukin-2  (IL-2),  IL-2 receptor a chain. 
granulocyte-macrophage  colony-stimulating  factor,  and  c-fos.' 
We  and  other  investigators  reported  that  leukemic  cells  from  pa- 
tients  with  adult  T-cell  leukemia  (ATL)  and  HTLV-I-transformed 
cell  lines  constitutively  produced  IL-la.'.'  IL-1  has  been  shown 
to  act  as  a  potent  osteoclast-activating  factor  and  cause  the  bone 
resorption.'  IL-I  can  also  produce  acute  inflammatory  protein  secre- 
tion by hepatocytes.  and  fever  in  Many  of these  phenomena 
are  also  frequently  associated  with  ATL.  Thus.  it  is  possible  that 
IL-1  activation  during  HTLV-I  infection  contributes  to  these  phe- 
nomena  and  clinical  symptoms.  However,  the  molecular  mechanism 
of activation  of  IL-la gene  in  HTLV-I-infected  T-cells  is  not known 
at  present.  Therefore,  we  examined  whether  HTLV-I  regulatory  gene 
product. Tax, was  indeed  able  to  transactivate  the  human  IL-la gene 
promoter. 
To examine  whether  the  tax gene  product  can  activate  the IL-la 
gene.  we  transfected  plasmids,  aH1 and  aH2. together  with  the 
tax expression  plasmid  pH2R40M8  into  Jurkat  cells  and  assayed 
chloramphenicol  acetyltransferase  (CAT)  activity  on  day  2  after 
transfection.  These  plasmids.  aH1 and aH2.  are hybrids of the hu- 
man IL-la promoter  and  the  CAT reporter  gene.  They  contain  the 
IL-la promoter  fragment  from -  1.437 to +l9  and  -1,437  to  +725. 
respectively  (Fig  1A).  As  shown  in Fig lB,  CAT  activity  was  mark- 
edly  increased  by  couansfection  of  a  tax  expression  plasmid 
(pH2R40M).  In  contrast.  a  HI and a  H2  plasmids  cotransfected 
with  a  control  plasmid  (pH2Rneo)  were  hardly  active  in  Jurkat  cells. 
Deletion  of  the  downstream  region  of  the IL-la gene  fragment  to 
the first exon  had  little  additional  effect  on  tux transactivation.  These 
results  suggest  that  common  promoter  elements  required  for  tax 
transactivation  are  present  in the region  from  positions  -1.437  to 
+  19. 
Tax  can  activate  transcription  through  two  structurally  distinct 
promoter  elements;  the  cyclic  AMP  response  element  (CRE)  and 
the  binding  site  for  NF-KB  transcription  factor.'  Interestingly,  the 
promoter region  of  IL-la does  not  contain  classical  CRE,  but  has 
a  single  NF-KB-like  sequence.  GGGGCATGCC  (- 1.065  to 
-  1.056).'  It is possible that tax might  transactivate  IL- la  promoter 
through  NF-KB.  The  fine deletion  analysis is currently  under  investi- 
gation in our laboratory. 
Activation  of  IL-la in HTLV-I-infected  cells  may  explain  the 
pathophysiology  associated  with  HTLV-I  infection.  including  the 
hypercalcemia.  osteolytic  bone  lesions,  elevation  of C-reactive pro- 
tein,  and  fever  that is prevalent in ATL. 
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ribavirin  therapy.  Thus,  adenovirus  had  become  a  serious  pathogen  in 
our  population  of  bone  marrow  transplantation  patients  for  which 
we had  no  effective  therapy. 
This  present  case  occurred  in  a  19-year-old  man  who  underwent 
T-cell-depleted  bone  marrow  transplantation  for  stage  IV  T-cell 
lymphoblastic  lymphoma.  The patient's  HLA-identical  15-year-old 
brother  was  his  donor.  His  peritransplant  course  was  uncomplicated. 
and he was  discharged  on  day  +  19. On  day  +42,  he  presented with 
anorexia.  nausea.  weight  loss, fever, mild  renal  insufficiency.  and 
gross  hematuria.  Adenovirus  was  cultured  from  his  urine,  and  cystos- 
copy  showed  ulcerations  of  the  bladder  mucosa.  The  patient  was 
requiring  multiple  transfusions  weekly  to  maintain  his  hematocrit 
secondary  to  his  significant  hemorrhagic  cystitis.  Renal  computed 
tomography  (CT)  scan  found  hypodense,  enlarged  ladneys.  The  pa- 
tient failed to improve  on  foscarnet  and  intravenous  Ig.  He became 
progressively  nauseated  and  anorexic.  eventually  requiring  hyperali- 
mentation  because  of significant  weight  loss. Adenovirus  was  contin- 
uously shed  in  his  urine.  There  were  no  other  coexisting  infections. 
This  dwindling  course  was  typical  for  the  previous  five patients  who 
had  fatal  adenovirus  infections. 
Because  we  had  not  had  a  survivor  with  this  syndrome.  we  at- 
tempted  to  treat  the  patient's  life-threatening  adenovirus  infection 
with  adoptive  immunotherapy. We infused  donor  leukocytes  (calcu- 
lated to  give  lo6  CD3'  cellslkg6  into  the  patient  on  day  +61. Over 
the  ensuing  S  weeks,  the  patient's  hematuria  cleared,  and  he  was 
able  to  sustain  nutrition  without  hyperalimentation.  Repeat  CT scan 
showed  normalization  of  renal  morphology.  Urine  adenovirus  cul- 
tures  turned  negative  on  day  "94.  Currently  (day  +228).  the  patient 
has  no  evidence  of  graft-versus-host  disease  or aplasia.  complica- 
tions  that  have  been  associated  with  donor  leukocyte  infusions.'~' 
This  patient  became  the  first survivor  at  our institution  having  this 
syndrome of  adenovirus  infection. 
The  successful  treatment  of adenovirus  with  donor  leukocyte  infu- 
sion  raises  the  possibility  that  this therapy  can  be widely  used  for 
many  types  of  serious  viral  infections  posttransplantation.  not just 
EBV. 
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